INMNasdaqPharmaceutical PreparationsFiscal year ends June 30
InMed Pharmaceuticals Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 9, 2026
$1.37+0.05 (+3.44%)
Close on Oct 19, 2026
- Market cap
- $6.42M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.73 (−34.98%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $6.42M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.97
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$12.56M
- EPS, diluted
- -$3.12
- Book value per share
- $0.23
- Diluted shares
- 5M
Eight years at a glance
Fiscal years 2019 to 2026, USD
Revenue
–
Gross profit
–
Operating income
–
Net income
-$12.56M
EPS, diluted
-$3.12
Free cash flow
–
Reported period